SEPN at a glance
Septerna, Inc. (SEPN, SEC CIK 1984086) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on August 25, 2026 and Form 4 insider filings as recently as September 10, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Septerna, Inc. (SEPN) reported revenue of $46.0 million (up 4174.5% from FY2024) and a net loss of $48.9 million. Diluted EPS was -$1.10.
- As of June 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Septerna, Inc. (SEPN) shares worth $275.0 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Long Daniel D. on September 1, 2026 of 3,333 shares at $37.83 per share.
- In the last 90 days, SEPN insiders reported 0 open-market purchases ($0) and 9 open-market sales ($72.3M) on Form 4, a net sale of $72.3M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $46.0M
- +4174.5% vs prior year
- Insiders · 90 days
- 0 buys · 9 sells
- Net −$72.3M
- 13F holders
- 25 funds
- $275.0M · +4 vs prior quarter
- Latest 8-K
- Aug 25, 2026
- Item 7.01 · Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- No newly added or changed risk factor identified; filing retains the 2025 Form 10-K risk framework
- Regulatory risk: extensive product-candidate regulation may delay or prevent required marketing approvals
- Clinical-development risk: no advanced clinical trials completed, leaving commercialization years away or uncertain
- Operational risk: dependence on third-party manufacturers, CROs, and CMOs for compliant supply and testing
- Liquidity risk: $516.5 million in cash, cash equivalents, and marketable securities expected to fund operations at least twelve months
AI summary of the SEPN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Rajiv Patni, M.D. appointed Chief Medical Officer
- Senior clinical leadership change potentially relevant to Septerna’s development strategy and program execution
Item 8.01: Other Events
- Rajiv Patni, M.D. appointed Chief Medical Officer effective August 24, 2026
- Senior leadership addition relevant to Septerna’s clinical-development strategy and medical oversight
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results and business highlights announced for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the detailed financial and operating information
Item EX-99.1: Item EX-99.1
- Q2 2026 revenue $26.7M, driven by Novo Nordisk collaboration amortization, milestones, and $11.2M research services
- Net loss narrowed to $13.0M from $24.8M, despite R&D increasing to $35.1M
Item 5.07: Submission of Matters to a Vote of Security Holders
- Shalini Sharp and Jake Simson elected as Class II directors for three-year terms ending at the 2029 annual meeting
- Sharp received 33,732,317 votes for; Simson received 33,716,857
AI summaries of SEPN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for SEPN
Don't miss the next SEPN filing
- Alerts as it files. A push when SEPN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut SEPN, by share count.
- Ask anything. An AI agent that reads every SEPN filing and answers with sources.
SEPN alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Patni Rajiv | A | Sep 8, 2026 | 275,000 | - |
| Long Daniel D. | Sell | Sep 1, 2026 | 3,333 | $37.83 |
| Long Daniel D. | M | Sep 1, 2026 | 3,333 | - |
| Long Daniel D. | M | Sep 1, 2026 | 3,333 | $2.76 |
| RA CAPITAL MANAGEMENT, L.P. | Sell | Aug 12, 2026 | 746,500 | $42.50 |
| Third Rock Ventures V, L.P. | Sell | Aug 12, 2026 | 147,059 | $50.27 |
| Third Rock Ventures V, L.P. | Sell | Aug 12, 2026 | 141 | $51.08 |
| RA CAPITAL MANAGEMENT, L.P. | Sell | Aug 12, 2026 | 746,500 | $42.50 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $151K | $1.1M | $46.0M |
| Operating Income | - | -$80.8M | -$68.3M |
| Net Income | - | -$71.8M | -$48.9M |
| Op. Margin | - | -7518.4% | -148.6% |
| Net Margin | - | -6678.9% | -106.4% |
| Balance Sheet | |||
| Total Assets | $130.9M | $456.6M | $596.2M |
| Equity | -$38.4M | $420.0M | $381.9M |
| ROE | - | -17.1% | -12.8% |
| Per Share | |||
| EPS | $0.29 | $-7.26 | $-1.10 |
| Cash Flow | |||
| Operating CF | - | -$67.5M | $110.2M |
| CapEx | - | $2.1M | $518K |
Source: XBRL data in Septerna, Inc. (SEPN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate SEPN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 25 | $275.0M |
| Q1 2026 | 21 | $182.6M |
| Q4 2025 | 21 | $209.7M |
| Q3 2025 | 19 | $111.4M |
| Q2 2025 | 19 | $56.1M |
| Q1 2025 | 14 | $21.4M |
| Q4 2024 | 11 | $66.5M |
- Goldman Sachs Group+156.3K (+5%)
- Two Sigma Investments+145.5K (+193%)
- BlackRock+109.9K (+6%)
- Northern Trust+36.6K (+22%)
- Vanguard Portfolio Management LLC+35.1K (+18%)
- Millennium Management−73.5K (-59%)
- Invesco Ltd−58.8K (-71%)
- BNY Mellon−2.5K (-4%)
- FMR LLC (Fidelity)−206 (-1%)
- Dimensional Fund Advisors+75.3K
- D.E. Shaw & Co+46.5K
- Franklin Resources+18.6K
- Citadel Advisors LLC+6.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 130 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
SEPN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 8-K | Aug 25, 2026 | - | Analysis | - |
| 4 | Aug 14, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 5, 2026 | - | - | - |
| 4 | Jul 17, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 8-K | Jun 30, 2026 | - | Analysis | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 16, 2026 | - | - | - |
| 4 | May 28, 2026 | - | - | |
| 8-K | May 11, 2026 | - | Analysis | |
| 10-Q | May 11, 2026 | Mar 31, 2026 | Analysis |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
SEPN SEC filings: frequently asked questions
Are SEPN insiders buying or selling?
In the last 90 days, Septerna, Inc. (SEPN) officers, directors and 10% owners reported no open-market purchases and 9 open-market sales worth $72.3 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold SEPN stock?
As of June 30, 2026, the largest Septerna, Inc. (SEPN) holders among the 13F filers tracked by SignalX were Goldman Sachs Group ($102.6 million), BlackRock ($64.7 million), Vanguard Capital Management LLC ($40.9 million), State Street Corp ($21.9 million), Vanguard Portfolio Management LLC ($7.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was SEPN's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Septerna, Inc. (SEPN) reported revenue of $46.0 million (up 4174.5% from FY2024) and a net loss of $48.9 million. Diluted EPS was -$1.10. The figures come from the XBRL data in the 10-K.
What did SEPN report in its latest 8-K?
Septerna, Inc. (SEPN) filed an 8-K on August 25, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). Rajiv Patni, M.D. appointed Chief Medical Officer.
What are the latest SEPN SEC filings?
Septerna, Inc. (SEPN) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on August 25, 2026 and a Form 4 insider filing on September 10, 2026.
What is SEPN's SEC CIK number?
Septerna, Inc. (SEPN)'s SEC Central Index Key (CIK) is 1984086. EDGAR lists every SEPN filing under that number.
Ask anything about SEPN
The research agent reads SEPN's filings, financials, insider trades and 13F holders, then answers with sources.